Literature DB >> 22588842

Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block.

Brigitte Lampe1, Christoph Hammerstingl, Jörg Otto Schwab, Fritz Mellert, Birgit Stoffel-Wagner, Andreas Grigull, Rolf Fimmers, Bernhard Maisch, Georg Nickenig, Thorsten Lewalter, Alexander Yang.   

Abstract

BACKGROUND: The impact of atrial fibrillation (AF) on heart failure (HF) was evaluated in patients with preserved left ventricular (LV) function and long-term right ventricular (RV) pacing for complete heart block.
METHODS: Clinical, echocardiographic, and laboratory parameters of HF were assessed in 35 patients with established AF who had undergone ablation of the atrioventricular node and pacemaker implantation (Group A) and 31 patients who received dual-chamber pacing for spontaneous complete heart block (Group B).
RESULTS: During a follow-up period of 12.7 ± 7.5 years, New York Heart Association (NYHA) functional class increased from 1.3 ± 0.5 to 2.1 ± 0.6 (p < 0.0001) in Group A, and from 1.3 ± 0.4 to 1.6 ± 0.7 (p < 0.01) in Group B. Left ventricular ejection fraction (LVEF) decreased from 59.7 ± 5.1 to 53.0 ± 8.2 (p < 0.0001) in Group A, but remained stable (58.6 ± 4.2 vs. 56.9 ± 7.0 %, p = 0,21) in Group B. At the end of follow-up, markers of LV function were moderately depressed in Group A compared with those in Group B: NYHA class 2.1 ± 0.6 versus 1.6 ± 0.7, p = 0.001; LVEF 53.0 ± 8.2 versus 56.9 ± 7.0 %, p < 0.05; LV diastolic diameter 53.6 ± 5.8 mm versus 50.7 ± 4.9 mm, p < 0.05; N-terminal pro-brain natriuretic peptide (NT-proBNP) 1116.8 ± 883.9 versus 622.9 ± 1059.4 pg/ml, p < 0.05. Progression of paroxysmal AF to permanent AF during follow-up was common, while new onset of AF was rare. Permanent AF was an independent predictor of declining LVEF >10 %, increasing NYHA class ≥1, and NT-proBNP levels >1,000 pg/ml.
CONCLUSIONS: Permanent AF was associated with adverse effects on LV function and symptoms of HF in patients with long-term RV pacing for complete heart block, and appears to play an important role in the development of HF in this specific patient cohort.

Entities:  

Mesh:

Year:  2012        PMID: 22588842     DOI: 10.1007/s00392-012-0468-7

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  33 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation.

Authors:  Laurens F Tops; Martin J Schalij; Eduard R Holman; Lieselot van Erven; Ernst E van der Wall; Jeroen J Bax
Journal:  J Am Coll Cardiol       Date:  2006-09-27       Impact factor: 24.094

3.  Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation.

Authors:  Axel Buob; Jens Jung; Stephanos Siaplaouras; Hans-Ruprecht Neuberger; Christian Mewis
Journal:  Pacing Clin Electrophysiol       Date:  2006-06       Impact factor: 1.976

4.  Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the 'Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)' study.

Authors:  Reinhard C Funck; Jean-Jacques Blanc; Hans-Helge Mueller; Carmen Schade-Brittinger; Christophe Bailleul; Bernhard Maisch
Journal:  Europace       Date:  2006-08       Impact factor: 5.214

5.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

6.  Total atrioventricular nodal ablation increases atrial fibrillation burden in patients with paroxysmal atrial fibrillation despite continuation of antiarrhythmic drug therapy.

Authors:  Rik Willems; D George Wyse; Anne M Gillis
Journal:  J Cardiovasc Electrophysiol       Date:  2003-12

7.  N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.

Authors:  Kristen K Patton; Patrick T Ellinor; Susan R Heckbert; Robert H Christenson; Christopher DeFilippi; John S Gottdiener; Richard A Kronmal
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

8.  AV nodal ablation and pacemaker implantation improves hemodynamic function in atrial fibrillation.

Authors:  Yoshihide Takahashi; Iesaka Yoshito; Atsushi Takahashi; Tomoo Harada; Takeshi Mitsuhashi; Kinya Shirota; Koichiro Kumagai; Norihito Nuruki; Takayoshi Shiraishi; Junichi Nitta; Hiroshi Ito
Journal:  Pacing Clin Electrophysiol       Date:  2003-05       Impact factor: 1.976

9.  Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: rationale and design of the PREVENT-HF study.

Authors:  Eduardo de Teresa; Juan José Gómez-Doblas; Gervasio Lamas; Javier Alzueta; Ignacio Fernández-Lozano; Erik Cobo; Xavier Navarro; Francisco Navarro-López; Martin Stockburger
Journal:  Europace       Date:  2007-04-25       Impact factor: 5.214

10.  Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction.

Authors:  Frank Edelmann; Raoul Stahrenberg; Götz Gelbrich; Kathleen Durstewitz; Christiane E Angermann; Hans-Dirk Düngen; Thomas Scheffold; Christian Zugck; Bernhard Maisch; Vera Regitz-Zagrosek; Gerd Hasenfuss; Burkert M Pieske; Rolf Wachter
Journal:  Clin Res Cardiol       Date:  2011-03-17       Impact factor: 5.460

View more
  5 in total

1.  Impact of left ventricular conduction defect with or without need for permanent right ventricular pacing on functional and clinical recovery after TAVR.

Authors:  Marcel Weber; Eva Brüggemann; Robert Schueler; Diana Momcilovic; Jan-Malte Sinning; Alexander Ghanem; Nikos Werner; Eberhard Grube; Wolfgang Schiller; Fritz Mellert; Armin Welz; Georg Nickenig; Christoph Hammerstingl
Journal:  Clin Res Cardiol       Date:  2015-05-13       Impact factor: 5.460

2.  Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study.

Authors:  V Simopoulos; G Tagarakis; A Hatziefthimiou; I Skoularigis; F Triposkiadis; V Trantou; N Tsilimingas; I Aidonidis
Journal:  Clin Res Cardiol       Date:  2014-08-19       Impact factor: 5.460

3.  Impact of real-time contact force and impedance measurement in pulmonary vein isolation procedures for treatment of atrial fibrillation.

Authors:  Reza Wakili; Sebastian Clauss; Viola Schmidt; Michael Ulbrich; Anton Hahnefeld; Franziska Schüssler; Johannes Siebermair; Stefan Kääb; Heidi L Estner
Journal:  Clin Res Cardiol       Date:  2013-10-06       Impact factor: 5.460

4.  Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure.

Authors:  Michael Behnes; Martina Brueckmann; Siegfried Lang; Christel Weiß; Parviz Ahmad-Nejad; Michael Neumaier; Martin Borggrefe; Ursula Hoffmann
Journal:  Clin Res Cardiol       Date:  2013-10-22       Impact factor: 5.460

5.  Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial.

Authors:  Giuseppe Boriani; Raymond Tukkie; Antonis S Manolis; Lluis Mont; Helmut Pürerfellner; Massimo Santini; Giuseppe Inama; Paolo Serra; João de Sousa; Giovanni Luca Botto; Lorenza Mangoni; Andrea Grammatico; Luigi Padeletti
Journal:  Eur Heart J       Date:  2014-04-25       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.